SCHEMBL1844115

SCHEMBL1844115

COc1ccc(CCl)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
RAB9A P51151 1/20 0.44
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
MBOAT4 Q96T53 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GFER P55789 1/20 0.38
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29987012 1.00 ALDH1A1 (0.44) ALDH1A1KDM4ETDP1RAB9ACA12
Hydrochloric Acid SCHEMBL10962311 0.98 ALDH1A1 (0.46) ALDH1A1KDM4ETDP1RAB9ACA12
SCHEMBL9429978 0.85 RAB9A (0.50) ALDH1A1KDM4ETDP1RAB9ASMN1; SMN2
SCHEMBL1581469 0.81 PDE10A (0.43) ALDH1A1KDM4ERAB9ACA12CA1
Hydrochloric Acid SCHEMBL9265592 0.80 MAPT (0.50) ALDH1A1KDM4ETDP1RAB9AMEN1
SCHEMBL19432655 0.79 MBOAT4 (0.43) ALDH1A1RAB9ACA12CA1CA2
SCHEMBL5032709 0.79 CA12 (0.40) CA12CA1CA2CA7CA9
SCHEMBL10002478 0.79 MAOB (0.43) ALDH1A1TDP1RAB9ACA12CA1
SCHEMBL21909726 0.79 CA12 (0.40) CA12CA1CA2CA7CA9
SCHEMBL22959296 0.79 IDO1 (0.48) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 US disclosed
US-20260035361-A1 COMPOUNDS FOR MODULATING HUR (ELAVL1) SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) 2026-02-05 US disclosed
EP-4077306-B1 COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION INC (US) 2025-05-07 EP disclosed
US-20240368133-A1 Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling CONFO THERAPEUTICS N.V. (BE) 2024-11-07 US disclosed
US-12036291-B2 Probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2024-07-16 US disclosed
CN-118159530-A Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling 康福治疗有限公司 2024-06-07 CN disclosed
EP-4377307-A1 COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING Confo Therapeutics N.V. (BE) 2024-06-05 EP disclosed
US-11992535-B2 Compounds and probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2024-05-28 US disclosed
CN-118005611-A Probes for imaging huntingtin CHDI基金会股份有限公司 2024-05-10 CN disclosed
EP-3455224-B1 SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF BAYER AG (DE) 2024-03-27 EP disclosed
EP-1318140-A1 NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS Mitsubishi Pharma Corporation (JP) 2003-06-11 EP disclosed
US-6194437-B1 ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS WARNER-LAMBERT COMPANY 2001-02-27 US disclosed
EP-0920424-A1 NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1999-06-09 EP disclosed
WO-1998007718-A1 NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1998-02-26 WO disclosed
US-5389650-A Antiinflammatory agents, anticoagulants, antispasmodic agents MERCK FROSST CANADA, INC. (CA) 1995-02-14 US disclosed
WO-1994013662-A1 (AZAARYLMETHOXY)INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1994-06-23 WO disclosed
WO-1994011378-A1 ARYL THIOPYRANO[2,3,4-c,d]INDOLES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1994-05-26 WO disclosed
US-5314900-A Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis MERCK FROSST CANADA, INC. (CA) 1994-05-24 US disclosed
EP-0535923-A1 (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis MERCK FROSST CANADA INC. (CA) 1993-04-07 EP disclosed
US-4230714-A Imidazole therapeutic agents PFIZER INC. (US) 1980-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF NAMPT, NNMT, SARM1 ALDH1A1 2719/4885KDM4E 3382/4885TDP1 3638/4885
US-20240368133-A1 Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling AGTR2, AGTR1, OPRL1 ALDH1A1 2919/4885KDM4E 4592/4885TDP1 3045/4885
US-12036291-B2 Probes for imaging huntingtin protein HTT, HYPK, HSPBP1 ALDH1A1 3976/4885KDM4E 4585/4885TDP1 540/4885
US-11992535-B2 Compounds and probes for imaging huntingtin protein HTT, HYPK, HSPBP1 ALDH1A1 4528/4885KDM4E 4698/4885TDP1 231/4885
US-20260035361-A1 COMPOUNDS FOR MODULATING HUR (ELAVL1) ELAVL1, ELAVL3, HNRNPL ALDH1A1 1434/4885KDM4E 4185/4885TDP1 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.